Immunogenicity of panitumumab in combination chemotherapy clinical trials

BACKGROUND: Panitumumab is a fully human antibody against the epidermal growth factor receptor that is indicated for the treatment of metastatic colorectal cancer (mCRC) after disease progression on standard chemotherapy. The purpose of this analysis was to examine the immunogenicity of panitumumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Weeraratne, Dohan, Chen, Alin, Pennucci, Jason J, Wu, Chi-Yuan, Zhang, Kathy, Wright, Jacqueline, Pérez-Ruixo, Juan José, Yang, Bing-Bing, Kaliyaperumal, Arunan, Gupta, Shalini, Swanson, Steven J, Chirmule, Narendra, Starcevic, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3231982/
https://www.ncbi.nlm.nih.gov/pubmed/22070868
http://dx.doi.org/10.1186/1472-6904-11-17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3231982/
https://www.ncbi.nlm.nih.gov/pubmed/22070868
http://dx.doi.org/10.1186/1472-6904-11-17

Ejemplares similares